Pharmaceuticals, Biotechnology and Life Sciences
Gilead’s company Kite’s trial for KTE-X19, its chimeric antigen receptor T cell therapy for adults with ALL (leukemia), resulted in…
Bristol-Myers Squibb will transfer $3.8 billion of U.S. pension obligations through a full termination of its U.S. Retirement Income Plan.…
AstraZeneca will divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal for uprfont payments of $815 million.
Novartis’s Biologics License Application (BLA) for Zolgensma, designed to tackle the genetic root cause of spinal muscular atrophy (SMA) Type 1, a deadly neuromuscular disease, was accepted by the U.S. Food and Drug Administration (FDA).
Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the…
Shield Therapeutics said Monday that US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA)…
Tiziana Life Sciences has completed patient enrollment in the ongoing Phase 2a clinical a single-arm, repeated-dose, 6-month duration study of Milciclib for certain patients with unresectable or metastatic HCC, with the topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.
Shire got the good news from the European Commission (EC) for Marketing Authorisation for Takhzyro injection, for prevention of recurrent…
Oasmia Pharmaceutical has made a deal with Baxter BioPharma Solutions to manufacture Apealea in its site in Germany, so Oasmia can focus on other products in its own facilities.
Novartis’s Gilenya became the first and only oral disease-modifying treatment for young patients with relapsing-remitting forms of multiple sclerosis (RRMS),…